Optimising Systemic Therapy in Metastatic Colorectal Cancer

Full Article

EP Hui

Hong Kong J Radiol 2013;16(Suppl):S17-22

The last 30 years have witnessed numerous advances in the management of metastatic colorectal cancer leading to an expansion in treatment options and improvement in treatment outcomes. The management of metastatic colorectal cancer involves an individualised treatment strategy based on evaluation of treatment goals for different patient subgroups, taking into account a variety of tumour-, host-, and treatment-related factors. Available systemic therapy includes chemotherapy regimens that can be combined with targeted agents such as anti–vascular endothelial growth factor antibodies (e.g. bevacizumab) and anti–epidermal growth factor receptor antibodies (e.g. cetuximab, panitumumab) to yield improved clinical outcomes. This article discusses recent clinical data on systemic therapy for metastatic colorectal cancer using different treatment combinations in various clinical settings.





過去30年間轉移性結直腸癌治療的進展帶來了更多的治療選擇,並改善了治療結果。轉移性結直腸癌的治療,涉及根據病人亞組評估而定的個人化治療目標,需要考慮多個腫瘤、宿主及治療相關的因素。現有的全身性治療包括:可與標靶藥物例如抗血管內皮生長因子抗體(如貝伐株單抗bevacizumab )及抗上皮生長因子受體抗體(如西妥昔單抗cetuximab、帕尼單抗panitumumab )合併使用的化療方案,以達致更好的臨床結果。本文討論了在各種臨床情況下,採用不同治療組合對轉移性結直腸癌進行全身性治療的近期臨床數據。